TI
NDRM

Trexquant Investment’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Trexquant Investment’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,582
Closed -$316K – 1214
2017
Q2 		$316K Buy
+10,582
New +$274K 0.09% 442
2016
Q1 		– Sell
-12,798
Closed -$218K – 1385
2015
Q4 		$218K Buy
+12,798
New +$249K 0.02% 923

Other funds holding NDRM

AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
SAM
Sandell Asset Management New York $179M AUM 65.55% 1-Year Est. Return
OP
Omni Partners London, United Kingdom $2.03B AUM 126.33% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
CFIC
City Financial Investment Company London, United Kingdom $562M AUM 5.93% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Trexquant Investment's NDRM Position: Q3 2017 in Review

Trexquant Investment sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q3 2017, closing a stake of 10,582 shares — an estimated $316K sold.

Trexquant Investment first reported a position in NDRM in Q4 2015 and held it in 2 quarters. The position peaked at $316K in Q2 2017. 81 funds tracked by Wall St. Rank hold NDRM as of Q3 2017.

  • Trexquant Investment reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q3 2017 after selling out during the quarter.
  • Trexquant Investment sold 10,582 NeuroDerm Ltd. Ordinary Shares shares in Q3 2017, an estimated $316K.
  • Trexquant Investment first reported a position in NeuroDerm Ltd. Ordinary Shares in Q4 2015 and held it in 2 quarters.
  • Trexquant Investment's NeuroDerm Ltd. Ordinary Shares position peaked at $316K in Q2 2017.
  • 81 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q3 2017.

Based on Trexquant Investment's 13F filing for Q3 2017, filed 9 Nov 2017.